{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:49:22Z","timestamp":1787759362814,"version":"build-2784847793"},"reference-count":21,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      Carbapenems are considered treatment of choice for bacteremia caused by potential AmpC-producing bacteria, including\n                      <jats:italic toggle=\"yes\">Enterobacter<\/jats:italic>\n                      spp. We aimed to compare mortality following carbapenem vs. alternative antibiotics for the treatment of\n                      <jats:italic toggle=\"yes\">Enterobacter<\/jats:italic>\n                      spp. bacteremia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective study in two centers in Israel. We included hospitalized patients with\n                      <jats:italic toggle=\"yes\">Enterobacter<\/jats:italic>\n                      bacteremia treated with third-generation cephalosporins (3GC), piperacillin\/tazobactam, quinolones, or carbapenem monotherapy as the main antibiotic in the first week of treatment, between 2010 and 2017. Cefepime was excluded due to nonavailability during study years. The primary outcome was 30-day all-cause mortality. Univariate and multivariate analyses were conducted, introducing the main antibiotic as an independent variable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Two hundred seventy-seven consecutive patients were included in the analyses. Of these, 73 were treated with 3GC, 39 with piperacillin\/tazobactam, 104 with quinolones, and 61 with carbapenems. All-cause 30-day mortality was 16% (45 patients). The type of antibiotics was not significantly associated with mortality on univariate or multivariate analyses. With carbapenems as reference, adjusted odds ratios (ORs) for mortality were 0.708, 95% confidence interval (CI) 0.231\u20132.176 with 3GC; OR 1.172, 95% CI 0.388\u20133.537 with piperacillin\/tazobactam; and OR 0.586, 95% CI 0.229\u20131.4 with quinolones. The main antibiotic was not associated with repeated growth of\n                      <jats:italic toggle=\"yes\">Entrobacter<\/jats:italic>\n                      spp. in blood cultures or other clinical specimens. Resistance development was observed with 3GC and piperacillin\/tazobactam.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Carbapenem treatment was not advantageous to alternative antibiotics, including 3GC, among patients with\n                      <jats:italic toggle=\"yes\">Enterobacter<\/jats:italic>\n                      spp. bacteremia in an observational study.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/mdr.2020.0234","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T11:27:19Z","timestamp":1597750039000},"page":"410-414","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment of Bacteremia Caused by\n                    <i>Enterobacter<\/i>\n                    spp.: Should the Potential for AmpC Induction Dictate Therapy? A Retrospective Study"],"prefix":"10.1177","volume":"27","author":[{"given":"Genady","family":"Drozdinsky","sequence":"first","affiliation":[{"name":"Medicine E, Rabin Medical Center, Beilinson Hospital, Peta-Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Neuberger","sequence":"additional","affiliation":[{"name":"Infectious Disease Division, Rambam Health Care Campus, Haifa, Israel."},{"name":"Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stav","family":"Rakedzon","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ortal","family":"Nelgas","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonat","family":"Cohen","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurith","family":"Rudich","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Mushinsky","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Ben-Zvi","sequence":"additional","affiliation":[{"name":"Microbiology Laboratory, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[{"name":"Infectious Disease Division, Rambam Health Care Campus, Haifa, Israel."},{"name":"Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"Infectious Disease Unit, Beilinson Hospital, Peta-Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2016.1154538"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.06.004"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv346"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036-08"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.5.1107"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz173"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-8-585"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/423382"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit395"},{"key":"e_1_3_4_11_2","first-page":"386","volume":"47","author":"Harris P.N.A.","year":"2015","unstructured":"Harris P.N.A., , Alder L., , and Paterson D.L.. 2015. Antimicrobial susceptibility reporting and treatment selection for AmpC-producing Enterobacteriaceae: what do microbiologists and infectious disease practitioners actually practice? Pathology, 47:386\u2013388.","journal-title":"Antimicrobial susceptibility reporting and treatment selection for AmpC-producing Enterobacteriaceae: what do microbiologists and infectious disease practitioners actually practice? Pathology"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-017-0177-0"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268818002480"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz528"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.07.008"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz248"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01083-07"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.9.2628-2630.2001"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00079-17"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01823-12"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku351"},{"key":"e_1_3_4_22_2","unstructured":"Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response\u2014Full Text View\u2014ClinicalTrials.gov. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02437045."}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2020.0234","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0234","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:38:09Z","timestamp":1777667889000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2020.0234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"alternative-id":["10.1089\/mdr.2020.0234"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2020.0234","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}